# Support for the Conduct of Studies to Evaluate the Impact of Genetic Background and Potential Treatments of SARS-CoV-2 Induced Pneumonia

> **NIH NIH N01** · BATTELLE MEMORIAL INSTITU · 2022 · $50,000

## Abstract

COVID19 is a novel zoonosis which has the potential for severe complications. Approximately 20% of affected individuals develop severe pneumonia progressing to acute respiratory distress syndrome (ARDS). Complication rates increase with advanced age, and 6-15% of patients over 70 years die due to COVID19. Severe COVID19 is manifesting primarily as ARDS and respiratory failure, leading to high prevalence of prolonged intensive care utilization, and thus to overwhelmed medical facilities. Currently there is no proven treatment for COVID19 severe disease.
Keywords: SARS-CoV-2, COVID-19

## Key facts

- **NIH application ID:** 10700771
- **Project number:** 273201700005C-P00016-9999-18
- **Recipient organization:** BATTELLE MEMORIAL INSTITU
- **Principal Investigator:** BARNEY SPARROW
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $50,000
- **Award type:** —
- **Project period:** 2017-09-26 → 2023-09-25

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10700771

## Citation

> US National Institutes of Health, RePORTER application 10700771, Support for the Conduct of Studies to Evaluate the Impact of Genetic Background and Potential Treatments of SARS-CoV-2 Induced Pneumonia (273201700005C-P00016-9999-18). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10700771. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*